The ATP synthase inhibition induces an AMPK-dependent glycolytic switch of mesenchymal stem cells that enhances their immunotherapeutic potential

Conclusion: Altogether, our findings show that AMPK-dependent glycolytic reprogramming of MSC using an ATP synthase inhibitor contributes to their immunosuppressive and therapeutic functions, and suggest that pro-glycolytic drugs might be used to improve MSC-based therapy.

Source: Theranostics - January 15, 2021 Category: Molecular Biology Authors: Rafael Contreras-Lopez, Roberto Elizondo-Vega, Noymar Luque-Campos, Mar í a Jos é Torres, Carolina Pradenas, Gautier Tejedor, Mar í a Jos é Paredes-Mart í nez, Ana Mar í a Vega-Letter, Mauricio Campos-Mora, Yandi Rigual-Gonzalez, Karina Oyarce, Ma Tags: Research Paper Source Type: research